Eli Lilly
Biosimilar developer, United States. 1 development product across 1 molecule: insulin glargine.
First approval in the Atlas: Sep 2014, Abasaglar, insulin glargine (EMA)
FDAproducts approved1
EMAproducts approved1
PMDAproducts approved1
HCproducts approved1
CDSCOproducts approved1
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Insulin glargine | Rezvoglar / Abasaglar LY2963016 | Dec 2021 | Sep 2014 | Dec 2014 | Sep 2015 | Aug 2017 | ยท |
Month shown is the first approval or registration of that product in that market.
Chronology
- EMASep 2014Abasaglar, insulin glargine
- PMDADec 2014Insulin Glargine BS [Lilly], insulin glargine
- HCSep 2015Basaglar, insulin glargine
- CDSCOAug 2017Basaglar, insulin glargine
- FDADec 2021Rezvoglar, insulin glargine
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.